```html

Wegovy (Semaglutide) – Adverse Reactions: A Comprehensive Medical Guide

Overview

Wegovy® (semaglutide) is a once‑weekly injectable glucagon‑like peptide‑1 (GLP‑1) receptor agonist that was FDA‑approved in 2021 for chronic weight management in adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight‑related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia.

While Wegovy is highly effective—clinical trials showed an average 15‑20 % body‑weight reduction after 68 weeks—it can cause a range of adverse reactions. Most are mild to moderate, but some may be serious and require prompt medical attention.

**Who is affected?** Anyone prescribed Wegovy can experience side effects, but the frequency and severity differ by age, sex, underlying health conditions, and concomitant medications. In the pivotal STEP trials, about 70 % of participants reported at least one adverse event, most commonly gastrointestinal (GI) symptoms.

**Prevalence of notable adverse reactions** (based on pooled data from STEP 1‑4, 2020‑2022):

• nausea – 46 %
• constipation – 30 %
• diarrhoea – 26 %
• vomiting – 23 %
• abdominal pain – 15 %
• pancreatitis – <0.2 % (rare but serious)
• gallbladder disease – 0.5 %
• hypoglycemia (mainly in patients with diabetes) – 4 %
• allergic skin reactions – 1 %

Symptoms

Adverse reactions may appear within days of the first injection or develop gradually after dose escalation. Below is a comprehensive list, grouped by system, with brief descriptions.

Gastro‑intestinal (most common)

• Nausea – queasy feeling, often worsens after meals and improves with smaller, low‑fat meals.
• Vomiting – may be isolated or accompany persistent nausea.
• Diarrhoea – loose, watery stools; can lead to dehydration if severe.
• Constipation – infrequent, hard stools; sometimes alternating with diarrhoea.
• Abdominal pain or discomfort – cramping, bloating, or a feeling of fullness.
• Indigestion (dyspepsia) – heartburn, belching, or sour taste.

Metabolic & Endocrine

• Hypoglycaemia – symptoms include shakiness, sweating, dizziness, hunger; most common in patients taking insulin or sulfonylureas.
• Elevated pancreatic enzymes – may be asymptomatic but signal pancreatitis risk.

Hepatobiliary

• Gallbladder disease – biliary colic, gallstones, or cholecystitis; presents with right‑upper‑quadrant pain, nausea, and possible fever.

Renal

• Acute kidney injury (AKI) – usually secondary to severe vomiting/diarrhoea causing dehydration.

Cardiovascular

• Increased heart rate – modest rise (≈2‑3 bpm) observed in some patients.

Dermatologic / Immunologic

• Injection‑site reactions – redness, swelling, itching, or bruising at the subcutaneous site.
• Allergic reactions – urticaria, rash, or, rarely, anaphylaxis.

Other

• Fatigue – feeling unusually tired, often linked to GI fluid loss.
• Headache – mild to moderate intensity.

Causes and Risk Factors

Wegovy works by mimicking the naturally occurring hormone GLP‑1, which slows gastric emptying, reduces appetite, and enhances insulin secretion. The same mechanisms that aid weight loss also underlie many adverse effects.

Primary causes

• Delayed gastric emptying – leads to nausea, fullness, and reflux.
• Increased pancreatic enzyme secretion – can irritate the pancreas, predisposing to pancreatitis.
• Altered bile‑acid metabolism – contributes to gallstone formation.

Risk factors for more severe reactions

• Pre‑existing gallbladder disease or history of gallstones.
• History of pancreatitis or pancreatic insufficiency.
• Severe renal impairment (eGFR < 30 mL/min/1.73 m²).
• Concurrent use of insulin, sulfonylureas, or other glucose‑lowering agents (higher hypoglycaemia risk).
• Rapid dose escalation or missing the recommended titration schedule.
• Pregnancy or breastfeeding (insufficient safety data).
• Allergy to semaglutide or any excipients in the formulation.

Diagnosis

Adverse reactions are primarily clinical diagnoses—healthcare providers rely on patient history, symptom timing, and physical examination. Specific tests are ordered when serious complications are suspected.

Step‑by‑step diagnostic approach

1. History & medication review – identify onset, severity, and pattern of symptoms; review dose and titration schedule.
2. Physical examination – assess abdominal tenderness, skin changes at injection sites, signs of dehydration (dry mucosa, low blood pressure).
3. Laboratory tests (as indicated)
   • Serum amylase & lipase – elevated levels suggest pancreatitis.
   • Liver function tests – to rule out hepatobiliary involvement.
   • Serum creatinine & electrolytes – evaluate renal function and dehydration.
   • Blood glucose – monitor for hypoglycaemia, especially if patient is diabetic.
4. Imaging (if warranted)
   • Abdominal ultrasound – first‑line for suspected gallstones or cholecystitis.
   • CT abdomen with contrast – definitive imaging for pancreatitis or severe abdominal pathology.
5. Allergy testing – skin prick or serum IgE testing when an allergic reaction is suspected, although most reactions are managed empirically.

Treatment Options

Management is tailored to the type and severity of the reaction. The core principle is to balance the therapeutic benefits of Wegovy with patient safety.

General measures

• Education on dose titration – start with 0.25 mg weekly, increase every 4 weeks as tolerated up to the target 2.4 mg.
• Hydration – encourage water and electrolyte‑rich fluids, especially if vomiting or diarrhoea occur.
• Dietary adjustments – small, low‑fat, high‑protein meals; avoid large, greasy meals that worsen nausea.

Specific pharmacologic interventions

• Antiemetics – ondansetron 4‑8 mg PO/IV q8h for persistent nausea/vomiting.
• Laxatives or stool softeners – polyethylene glycol (PEG) or docusate for constipation.
• Antidiarrheal agents – loperamide 2 mg after the first loose stool, then 2 mg after each subsequent loose stool (max 8 mg/day).
• Insulin or sulfonylurea dose reduction – to prevent hypoglycaemia when using Wegovy in diabetic patients.
• Pancreatitis management – immediate cessation of semaglutide, NPO status, IV fluids, analgesia, and hospital admission if lipase/amylase > 3× upper limit.
• Gallbladder disease – surgical consultation for cholecystectomy if symptomatic gallstones develop.

When to discontinue Wegovy

The drug should be stopped if any of the following occur:

• Confirmed acute pancreatitis.
• Severe, persistent nausea/vomiting causing weight loss > 5 % despite supportive care.
• Serious allergic reaction (e.g., anaphylaxis, Stevens‑Johnson syndrome).
• Significant renal impairment attributable to dehydration.

Alternative therapies

If Wegovy must be discontinued, other weight‑loss options include:

• Other GLP‑1 agonists with different titration schedules (e.g., liraglutide).
• Phentermine‑topiramate, naltrexone‑bupropion, or bupropion alone (consider contraindications).
• Comprehensive lifestyle programs (behavioral therapy, dietitian‑led nutrition plans, structured exercise).

Living with Wegovy (Semaglutide) Adverse Reactions

Many patients can continue therapy while effectively managing side effects. Below are practical tips for daily life.

Medication‑taking habits

• Inject on the same day each week, preferably in the evening to reduce daytime nausea.
• Rotate injection sites (abdomen, thigh, upper arm) to avoid local irritation.
• Keep a symptom diary – note timing, severity, and triggers.

Nutrition strategies

• Eat 4–5 small meals daily; include lean protein, non‑starchy vegetables, and healthy fats.
• Avoid carbonated drinks, caffeine, and high‑fat foods that may aggravate GI upset.
• If nausea persists, try ginger tea, peppermint, or a bland “BRAT” diet (bananas, rice, applesauce, toast) until symptoms improve.

Hydration & electrolyte balance

• Aim for ≥ 2 L of fluid per day; add a pinch of salt or an oral rehydration solution if diarrhoea is frequent.
• Monitor urine colour – dark yellow may signal dehydration.

Physical activity

• Start with low‑impact activities (walking, stretching) and gradually increase intensity as tolerance improves.
• Avoid vigorous exercise immediately after an injection if you feel nauseous.

When to contact your prescriber

• Symptoms last longer than 2 weeks or worsen despite the above measures.
• Any sign of pancreatitis (severe upper‑abdominal pain radiating to the back, accompanied by vomiting).
• Unexplained weight loss beyond the expected therapeutic effect.
• Signs of an allergic reaction such as rash, swelling, or difficulty breathing.

Prevention

Most adverse reactions can be minimized with careful planning.

• Follow the titration schedule exactly; do not jump to higher doses.
• Screen for gallbladder disease before initiating therapy—ultrasound if there’s a history of gallstones.
• Baseline labs – check fasting glucose, HbA1c, renal function, and pancreatic enzymes.
• Review concomitant medications—adjust insulin or sulfonylureas to lower hypoglycaemia risk.
• Educate patients about early GI symptoms and encourage early reporting.
• Avoid rapid weight loss (> 1 kg/week) beyond the trial protocol, as this is linked to gallstone formation.

Complications

If adverse reactions are ignored or untreated, they can lead to significant health problems.

• Pancreatitis – can progress to necrotizing pancreatitis, systemic inflammatory response, or chronic pancreatic insufficiency.
• Gallstone disease – may cause biliary colic, choledocholithiasis, or acute cholecystitis, potentially requiring emergency surgery.
• Severe dehydration – from persistent vomiting/diarrhoea, leading to acute kidney injury, electrolyte disturbances, and arrhythmias.
• Hypoglycaemia – especially dangerous in the elderly or those driving; can cause falls, seizures, or loss of consciousness.
• Allergic anaphylaxis – rare but life‑threatening, requiring immediate epinephrine.

When to Seek Emergency Care

For all other concerns, contact your primary care provider or the prescribing specialist within 24‑48 hours.

---

References

• Mayo Clinic. “Semaglutide (Wegovy) Injection.” Accessed June 2026.
• NIH, National Institute of Diabetes and Digestive and Kidney Diseases. “GLP‑1 Receptor Agonists.” 2024.
• STEP 1‑4 Clinical Trial Program. “Semaglutide for Weight Management.” New England Journal of Medicine, 2021. DOI:10.1056/NEJMoa2032183.
• American Diabetes Association. “Pharmacologic Approaches to Obesity.” Diabetes Care, 2023.
• Cleveland Clinic. “Gallbladder Disease and Rapid Weight Loss.” 2022.
• World Health Organization. “Pharmacovigilance and Medicine Safety.” 2023.

```